文献速递肿瘤 PET/CT

18F-氟妥昔洛司他(rhPSMA-7.3)PET/CT检查期间利尿可提高前列腺切除术后复发检出率:一项前瞻性II期试验

Diuresis During 18F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
PubMed 文献 · J Nucl Med · 2025-02-03

本前瞻性II期试验纳入20例前列腺切除术后生化复发(PSA≥0.1 ng/mL)男性,对比18F-氟妥昔洛司他PET/CT联合静脉呋塞米20 mg与未用呋塞米两种方案,发现联合呋塞米组膀胱活性显著降低,前列腺床区域复发检出率85%对60%(P=0.025),患者层面及盆腔、盆腔外区域检出率无差异。

要点

  • 联合呋塞米组膀胱SUVmax中位4.20、SUVmean中位2.95,均显著低于未用呋塞米组。
  • 前列腺床区域复发检出率联合呋塞米组85%(17/20)高于未用呋塞米组60%(12/20),P=0.025。
  • 患者层面及盆腔、盆腔外区域检出率两组无差异;未用呋塞米组3/20出现轻度非干扰性膀胱周围晕状伪影。

核心结论

  • 在前列腺癌根治术后生化复发且PSA≥0.1 ng/mL的男性中,18F-氟妥昔洛司他PET/CT联合低剂量呋塞米可进一步降低膀胱放射性强度并提高局部复发检出率。
  • 即使不使用利尿剂,单纯膀胱相对充盈也能降低膀胱活性,但程度不及使用利尿剂。

研究设计与样本

  • 前瞻性II期研究(NCT05779943),招募前列腺切除术后PSA升高至少0.1 ng/mL的前列腺癌男性。
  • 所有患者均接受两次18F-氟妥昔洛司他PET/CT扫描,一次随放射性示踪剂静脉给予呋塞米20 mg,另一次不用呋塞米。
  • 比较用与不用呋塞米两次PET/CT的SUVmean、SUVmax和膀胱体积,并比较两组扫描的前列腺癌病灶检出情况。
  • 20名男性完成两组扫描,中位PSA为0.61 ng/mL(四分位距0.18-1.15)。

主要发现

  • 联合呋塞米组膀胱活性显著低于未用呋塞米组:SUVmax中位4.20(范围1.70-19.80)对13.35(范围3.90-165.4),P=0.014;SUVmean中位2.95(范围0.80-17.60)对10.00(范围1.90-140.00),P=0.017。
  • 多变量分析显示呋塞米给药和膀胱充盈均为膀胱活性降低的独立协变量。
  • 前列腺床区域水平复发检出率联合呋塞米组为17/20(85%),未用呋塞米组为12/20(60%),P=0.025。
  • 患者层面、盆腔区域或盆腔外区域检出率两组间无差异。
  • 未用呋塞米组20次检查中3次出现轻度非干扰性膀胱周围晕状伪影,联合呋塞米组无伪影。

关键数值与推荐

  • 联合呋塞米方案:18F-氟妥昔洛司他PET/CT检查时随示踪剂静脉给予呋塞米20 mg并口服水化。
  • 入组标准:前列腺癌前列腺切除术后生化复发,PSA水平至少0.1 ng/mL。

临床怎么用

  • 作者结论指出,对前列腺癌切除术后生化复发且PSA≥0.1 ng/mL的男性,采用18F-氟妥昔洛司他PET/CT联合低剂量呋塞米策略可降低膀胱强度并提高局部复发检出。
  • 作者结论指出,即使不使用利尿剂,单纯膀胱相对充盈也能降低膀胱活性,但程度不及使用利尿剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged as a sensitive tool for PET imaging of prostate cancer (PCa) recurrence. Yet urinary bladder activity may obscure the visualization of prostate bed recurrence. Among the Food and Drug Administration-approved PSMA radiopharmaceuticals, 18F-flotufolastat (rhPSMA-7.3) has the lowest urinary excreted activity. We investigated the impact of diuresis with intravenous furosemide and oral hydration on bladder activity and PCa recurrence detection in patients with PCa after prostatectomy with biochemical recurrence. Methods: This phase II study (NCT05779943) prospectively recruited men with PCa after prostatectomy with a rising prostate-specific antigen (PSA) level of at least 0.1 ng/mL. All patients had 2 18F-flotufolastat PET/CT scans, one with 20 mg of furosemide administered intravenously with the radiotracer and the other without. SUVmean, SUVmax, and bladder volume were compared between the with- and without-furosemide PET/CT studies. PCa lesion detection was compared between the 2 sets of scans. Results: Twenty men with a median PSA of 0.61 ng/mL (interquartile range, 0.18-1.15) completed both sets of scans. Bladder activity was significantly lower for the with- than the without-furosemide studies, at a median SUVmax of 4.20 (range, 1.70-19.80) versus 13.35 (range, 3.90-165.4), respectively (P = 0.014), and a median SUVmean of 2.95 (range, 0.80-17.60) versus 10.00 (range, 1.90-140.00), respectively (P = 0.017). Multivariable analysis demonstrated that both furosemide administration and bladder distention were independent covariates for reduced bladder activity. At the prostate bed region level, the recurrence detection rates were 17 of 20 (85%) and 12 of 20 (60%) for the with- and without-furosemide studies, respectively (P = 0.025). No difference in detection rates was present at the per-patient, pelvic, or extrapelvic regions between the 2 sets of studies. Three of 20 without-furosemide studies had a mild noninterfering peribladder halo artifact, but none had an artifact with furosemide. Conclusion: In men with biochemical recurrence and a PSA level of at least 0.1 ng/mL after prostatectomy for PCa, a strategy with 18F-flotufolastat PET/CT and concordant low-dose furosemide further reduces urinary bladder intensity and increases local recurrence detection. Even without the use of a diuretic, relative bladder distension alone also reduces bladder activity, though not to the same degree as with a diuretic.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lawal IO, Mushtaq A, Jani AB, et al. Diuresis During 18F-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial. J Nucl Med. 2025. PMID: 39848765. doi:10.2967/jnumed.124.268574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。